2021 Q1 Form 10-Q Financial Statement
#000155905321000016 Filed on May 11, 2021
Income Statement
Concept | 2021 Q1 | 2020 Q1 |
---|---|---|
Revenue | $160.0K | $141.0K |
YoY Change | 13.48% | -24.19% |
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $11.13M | $9.740M |
YoY Change | 14.27% | -1.72% |
% of Gross Profit | ||
Research & Development | $21.14M | $15.25M |
YoY Change | 38.67% | 14.68% |
% of Gross Profit | ||
Depreciation & Amortization | $304.0K | $384.0K |
YoY Change | -20.83% | -0.26% |
% of Gross Profit | ||
Operating Expenses | $32.27M | $24.99M |
YoY Change | 29.13% | 7.99% |
Operating Profit | -$32.11M | -$24.85M |
YoY Change | 29.22% | 8.25% |
Interest Expense | $10.00K | $1.140M |
YoY Change | -99.12% | -50.43% |
% of Operating Profit | ||
Other Income/Expense, Net | $34.00K | $1.113M |
YoY Change | -96.95% | -51.33% |
Pretax Income | -$32.08M | -$23.74M |
YoY Change | 35.14% | 14.84% |
Income Tax | $4.700M | -$200.0K |
% Of Pretax Income | ||
Net Earnings | -$36.74M | -$23.57M |
YoY Change | 55.86% | 12.96% |
Net Earnings / Revenue | -22959.38% | -16715.6% |
Basic Earnings Per Share | -$0.91 | -$0.59 |
Diluted Earnings Per Share | -$0.91 | -$0.59 |
COMMON SHARES | ||
Basic Shares Outstanding | 40.25M shares | 39.91M shares |
Diluted Shares Outstanding | 40.25M shares |
Balance Sheet
Concept | 2021 Q1 | 2020 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $343.0M | $352.7M |
YoY Change | -2.75% | -14.0% |
Cash & Equivalents | $343.0M | $352.7M |
Short-Term Investments | ||
Other Short-Term Assets | $9.400M | $6.800M |
YoY Change | 38.24% | 33.33% |
Inventory | ||
Prepaid Expenses | ||
Receivables | $1.000K | $174.0K |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $352.3M | $359.7M |
YoY Change | -2.05% | -13.37% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $2.295M | $3.531M |
YoY Change | -35.0% | -29.04% |
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $338.0K | $1.115M |
YoY Change | -69.69% | 28.46% |
Total Long-Term Assets | $27.42M | $39.73M |
YoY Change | -30.99% | -10.4% |
TOTAL ASSETS | ||
Total Short-Term Assets | $352.3M | $359.7M |
Total Long-Term Assets | $27.42M | $39.73M |
Total Assets | $379.7M | $399.4M |
YoY Change | -4.93% | -13.08% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $4.212M | $3.297M |
YoY Change | 27.75% | 56.78% |
Accrued Expenses | $18.50M | $12.90M |
YoY Change | 43.41% | 10.26% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $23.46M | $17.09M |
YoY Change | 37.28% | 14.62% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $553.0K | $553.0K |
YoY Change | 0.0% | 0.0% |
Total Long-Term Liabilities | $121.7M | $127.3M |
YoY Change | -4.41% | -3.93% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $23.46M | $17.09M |
Total Long-Term Liabilities | $121.7M | $127.3M |
Total Liabilities | $145.1M | $144.4M |
YoY Change | 0.52% | -2.05% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$819.8M | -$695.5M |
YoY Change | 17.88% | 17.04% |
Common Stock | $442.0K | $399.0K |
YoY Change | 10.78% | 0.0% |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $234.6M | $255.0M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $379.7M | $399.4M |
YoY Change | -4.93% | -13.08% |
Cashflow Statement
Concept | 2021 Q1 | 2020 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$36.74M | -$23.57M |
YoY Change | 55.86% | 12.96% |
Depreciation, Depletion And Amortization | $304.0K | $384.0K |
YoY Change | -20.83% | -0.26% |
Cash From Operating Activities | -$33.67M | -$23.17M |
YoY Change | 45.32% | 32.88% |
INVESTING ACTIVITIES | ||
Capital Expenditures | -$50.00K | -$20.00K |
YoY Change | 150.0% | -84.62% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $0.00 | |
YoY Change | -100.0% | |
Cash From Investing Activities | -$48.00K | -$22.00K |
YoY Change | 118.18% | -82.11% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | $78.37M | $0.00 |
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | $81.33M | $151.0K |
YoY Change | 53758.94% | 2920.0% |
NET CHANGE | ||
Cash From Operating Activities | -$33.67M | -$23.17M |
Cash From Investing Activities | -$48.00K | -$22.00K |
Cash From Financing Activities | $81.33M | $151.0K |
Net Change In Cash | $47.61M | -$23.04M |
YoY Change | -306.67% | 31.25% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$33.67M | -$23.17M |
Capital Expenditures | -$50.00K | -$20.00K |
Free Cash Flow | -$33.62M | -$23.15M |
YoY Change | 45.23% | 33.76% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
CY2021Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2021Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001559053 | |
CY2021Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2016Q1 | prta |
Buildtosuit Lease Termof Contract
BuildtosuitLeaseTermofContract
|
P7Y9M30D | |
CY2021Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2021Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2021Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-03-31 | |
CY2021Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2021Q1 | dei |
Entity File Number
EntityFileNumber
|
001-35676 | |
CY2021Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
PROTHENA CORPORATION PUBLIC LIMITED COMPANY | |
CY2021Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
L2 | |
CY2021Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
98-1111119 | |
CY2021Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
77 Sir John Rogerson’s Quay, Block C | |
CY2021Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Grand Canal Docklands | |
CY2021Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Dublin 2, | |
CY2021Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
D02 VK60, | |
CY2021Q1 | dei |
Entity Address Country
EntityAddressCountry
|
IE | |
CY2021Q1 | dei |
Country Region
CountryRegion
|
353 | |
CY2021Q1 | dei |
City Area Code
CityAreaCode
|
1 | |
CY2021Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
236-2500 | |
CY2021Q1 | dei |
Security12b Title
Security12bTitle
|
Ordinary Shares, par value $0.01 per share | |
CY2021Q1 | dei |
Trading Symbol
TradingSymbol
|
PRTA | |
CY2021Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2021Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2021Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2021Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2021Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2021Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2021Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
44175792 | shares |
CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
342993000 | USD |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
295380000 | USD |
CY2021Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1000 | USD |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15000 | USD |
CY2021Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7955000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2537000 | USD |
CY2021Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1352000 | USD |
CY2020Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1352000 | USD |
CY2021Q1 | us-gaap |
Assets Current
AssetsCurrent
|
352301000 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
299284000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2295000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2551000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
16411000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17811000 | USD |
CY2021Q1 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
7022000 | USD |
CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
11644000 | USD |
CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1352000 | USD |
CY2020Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1352000 | USD |
CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
338000 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
333000 | USD |
CY2021Q1 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
27418000 | USD |
CY2020Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
33691000 | USD |
CY2021Q1 | us-gaap |
Assets
Assets
|
379719000 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
332975000 | USD |
CY2021Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4212000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4117000 | USD |
CY2021Q1 | prta |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
9355000 | USD |
CY2020Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
123121000 | USD |
CY2020Q4 | prta |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
9044000 | USD |
CY2021Q1 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
0 | USD |
CY2020Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
36000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
5617000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
5512000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4272000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
7139000 | USD |
CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
23456000 | USD |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
25848000 | USD |
CY2021Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
110242000 | USD |
CY2020Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
110242000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10884000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
12326000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
553000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
553000 | USD |
CY2021Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
121679000 | USD |
CY2020Q4 | prta |
Deferred Shares Share Issued
DeferredSharesShareIssued
|
0 | shares |
CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
145135000 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
148969000 | USD |
CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2021Q1 | prta |
Deferred Shares Par Value
DeferredSharesParValue
|
22 | |
CY2020Q4 | prta |
Deferred Shares Par Value
DeferredSharesParValue
|
22 | |
CY2021Q1 | prta |
Deferred Shares Value
DeferredSharesValue
|
0 | USD |
CY2020Q4 | prta |
Deferred Shares Value
DeferredSharesValue
|
0 | USD |
CY2020Q4 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
CY2021Q1 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
CY2021Q1 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
CY2020Q4 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
CY2020Q4 | prta |
Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
|
0 | shares |
CY2021Q1 | prta |
Deferred Shares Share Issued
DeferredSharesShareIssued
|
0 | shares |
CY2021Q1 | prta |
Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
|
0 | shares |
CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
442000 | USD |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
399000 | USD |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44175792 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44175792 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39921413 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
39921413 | shares |
CY2021Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1053906000 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
966636000 | USD |
CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-819764000 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-783029000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
234584000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
184006000 | USD |
CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
379719000 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
332975000 | USD |
CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
160000 | USD |
CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
141000 | USD |
CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
21144000 | USD |
CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15248000 | USD |
CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11125000 | USD |
CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9741000 | USD |
CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
32269000 | USD |
CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
24989000 | USD |
CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32109000 | USD |
CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24848000 | USD |
CY2021Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
11000 | USD |
CY2020Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
1137000 | USD |
CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
23000 | USD |
CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-24000 | USD |
CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
34000 | USD |
CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1113000 | USD |
CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-32075000 | USD |
CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-23735000 | USD |
CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
4660000 | USD |
CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-166000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36735000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23569000 | USD |
CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.91 | |
CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.59 | |
CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40250000 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39909000 | shares |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36735000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23569000 | USD |
CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
304000 | USD |
CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
384000 | USD |
CY2021Q1 | prta |
Sharebased Compensationnonrestructuring
SharebasedCompensationnonrestructuring
|
6176000 | USD |
CY2020Q1 | prta |
Sharebased Compensationnonrestructuring
SharebasedCompensationnonrestructuring
|
5536000 | USD |
CY2021Q1 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
4622000 | USD |
CY2020Q1 | us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
-495000 | USD |
CY2021Q1 | prta |
Amortizationofrightofuseasset
Amortizationofrightofuseasset
|
1400000 | USD |
CY2020Q1 | prta |
Amortizationofrightofuseasset
Amortizationofrightofuseasset
|
1345000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-14000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
106000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
5259000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
4278000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2851000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-748000 | USD |
CY2021Q1 | prta |
Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
|
1337000 | USD |
CY2020Q1 | prta |
Increase Decreasein Operating Lease Liability
IncreaseDecreaseinOperatingLeaseLiability
|
1236000 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-33666000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23167000 | USD |
CY2021Q1 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
48000 | USD |
CY2020Q1 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
22000 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-48000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-22000 | USD |
CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
78367000 | USD |
CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2960000 | USD |
CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
151000 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
81327000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
151000 | USD |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
47613000 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-23038000 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
298084000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
378427000 | USD |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
345697000 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
355389000 | USD |
CY2021Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
402000 | USD |
CY2020Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
417000 | USD |
CY2021Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
0 | USD |
CY2020Q1 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
24000 | USD |
CY2021Q1 | prta |
Receivable From Options Exercises
ReceivableFromOptionsExercises
|
123000 | USD |
CY2020Q1 | prta |
Receivable From Options Exercises
ReceivableFromOptionsExercises
|
0 | USD |
CY2021Q1 | prta |
Offering Costs Included In Accounts Payable And Accrued Liabilities
OfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
|
313000 | USD |
CY2020Q1 | prta |
Offering Costs Included In Accounts Payable And Accrued Liabilities
OfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
|
0 | USD |
CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
342993000 | USD |
CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
352685000 | USD |
CY2021Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1352000 | USD |
CY2020Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
0 | USD |
CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1352000 | USD |
CY2020Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2704000 | USD |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
345697000 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
355389000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
184006000 | USD |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6176000 | USD |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3083000 | USD |
CY2021Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
5500000 | USD |
CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
78054000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36735000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
234584000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
272921000 | USD |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5536000 | USD |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
151000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23569000 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
255039000 | USD |
CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-819800000 | USD |
CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
343000000.0 | USD |
CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation, research and development expenses and leases. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div> | |
CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Concentration of Risks</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receivables recorded in the Condensed Consolidated Balance Sheet include amounts due from a Roche entity located in Switzerland. Collaboration revenue recorded in the Condensed Consolidated Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, $2.3 million of the Company’s property and equipment, net were held in the U.S. and none were in Ireland. As of December 31, 2020, $2.6 million of the Company's property and equipment, net were held in the U.S. and none were in Ireland. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all preclinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</span></div> | |
CY2021Q1 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
9350000 | USD |
CY2020Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
9343000 | USD |
CY2021Q1 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
1318000 | USD |
CY2020Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
1278000 | USD |
CY2021Q1 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
1424000 | USD |
CY2020Q4 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
1423000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
12092000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
12044000 | USD |
CY2021Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
9797000 | USD |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
9493000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2295000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2551000 | USD |
CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
300000 | USD |
CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
400000 | USD |
CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3516000 | USD |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5927000 | USD |
CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
510000 | USD |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
696000 | USD |
CY2021Q1 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
246000 | USD |
CY2020Q4 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
516000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4272000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
7139000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36735000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23569000 | USD |
CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40250000 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39909000 | shares |
CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.91 | |
CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.59 | |
CY2016Q1 | prta |
Operating Lease Area
OperatingLeaseArea
|
128751 | sqft |
CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y9M | |
CY2016Q1 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2023-12-31 | |
CY2016Q2 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
39200000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1600000 | USD |
CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1600000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1500000 | USD |
CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1500000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0425 | |
CY2016Q4 | prta |
Operating Leases Improvement Allowance
OperatingLeasesImprovementAllowance
|
14200000 | USD |
CY2018Q3 | prta |
Operating Leases Sublease Rentals Areaof Sublease Rental
OperatingLeasesSubleaseRentalsAreaofSubleaseRental
|
46641 | sqft |
CY2021Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
700000 | USD |
CY2020Q1 | us-gaap |
Sublease Income
SubleaseIncome
|
700000 | USD |
CY2018Q3 | prta |
Subleaserentals Annual Base Rent Initial Amount
SubleaserentalsAnnualBaseRentInitialAmount
|
2700000 | USD |
CY2018Q3 | prta |
Operating Leases Sublease Rentals Percent Annual Rent Increase
OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
|
0.035 | |
CY2018Q3 | prta |
Operating Leases Sublease Rentals Termof Contract
OperatingLeasesSubleaseRentalsTermofContract
|
P5Y2M12D | |
CY2018Q3 | prta |
Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord
OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
|
0.50 | |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4662000 | USD |
CY2021Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
|
2216000 | USD |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
6350000 | USD |
CY2021Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
|
3047000 | USD |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
6535000 | USD |
CY2021Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
|
3019000 | USD |
CY2021Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
|
0 | USD |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
17547000 | USD |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
0 | USD |
CY2021Q1 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
8282000 | USD |
CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1027000 | USD |
CY2021Q1 | prta |
Lessee Operating Lease Liability Nominal Payments
LesseeOperatingLeaseLiabilityNominalPayments
|
19000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
16501000 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation
PurchaseObligation
|
11900000 | USD |
CY2021Q1 | us-gaap |
Contractual Obligation
ContractualObligation
|
700000 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation
PurchaseObligation
|
11921000 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
|
11921000 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
0 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
0 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
0 | USD |
CY2021Q1 | us-gaap |
Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
|
0 | USD |
CY2021Q1 | prta |
Purchase Obligation To Be Paid After Year Four
PurchaseObligationToBePaidAfterYearFour
|
0 | USD |
CY2021Q1 | prta |
Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
|
12661000 | USD |
CY2021Q1 | prta |
Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
|
12056000 | USD |
CY2021Q1 | prta |
Purchase And Contractual Obligation Due In Year One
PurchaseAndContractualObligationDueInYearOne
|
70000 | USD |
CY2021Q1 | prta |
Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
|
70000 | USD |
CY2021Q1 | prta |
Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
|
60000 | USD |
CY2021Q1 | prta |
Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
|
60000 | USD |
CY2021Q1 | prta |
Purchase And Contractual Obligation Due After Fourth Year
PurchaseAndContractualObligationDueAfterFourthYear
|
345000 | USD |
CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44175792 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44175792 | shares |
CY2021Q1 | prta |
Numberof Votes
NumberofVotes
|
1 | vote |
CY2021Q1 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
CY2021Q1 | prta |
Deferred Shares Par Value
DeferredSharesParValue
|
22 | |
CY2021Q1 | prta |
Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
|
0 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
2550977 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1372587 | shares |
CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
1455450 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P4Y | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8825499 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
16.23 | |
CY2021Q1 | prta |
Number Of Ordinary Shares Tendered For Exchange Under The Option Exchage
NumberOfOrdinarySharesTenderedForExchangeUnderTheOptionExchage
|
2100000 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1400000 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
22.85 | |
CY2021Q1 | prta |
Share Based Compensation Arrangement By Share Based Payment Award Options Minimum Exchange Threshold Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumExchangeThresholdExercisePrice
|
17.63 | |
CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
44800000 | USD |
CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M7D | |
CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6176000 | USD |
CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5536000 | USD |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.813 | |
CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.815 | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.010 | |
CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.012 | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.09 | |
CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
8.32 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8744765 | shares |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
20.42 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y2M8D | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
4656000 | USD |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2550977 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
22.39 | |
CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
229379 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
13.43 | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
236876 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
30.60 | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
2003988 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
40.98 | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8825499 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
16.23 | |
CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y5M8D | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
81230000 | USD |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
8290411 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
16.15 | |
CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P7Y4M13D | |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
77128000 | USD |
CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
3356692 | shares |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
14.60 | |
CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y5M23D | |
CY2021Q1 | prta |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
|
37958000 | USD |
CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1372587 | shares |
CY2021Q1 | prta |
Share Based Compensation Arrangement By Share Based Payment Award Unvested Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsForfeituresInPeriod
|
179959 | shares |
CY2021Q1 | prta |
Share Based Compensation Arrangement By Share Based Payment Award Unvested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedOptionsExpirationsInPeriod
|
1934446 | shares |
CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
4700000 | USD |
CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-200000 | USD |
CY2021Q1 | prta |
Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
|
100000 | USD |
CY2020Q1 | prta |
Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision
SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision
|
100000 | USD |
CY2021Q1 | prta |
Deferred Tax Assets Period Increase Decrease
DeferredTaxAssetsPeriodIncreaseDecrease
|
4600000 | USD |
CY2021Q1 | prta |
Deferred Tax Assets Period Increase Decrease Tax Cuts And Jobs Act
DeferredTaxAssetsPeriodIncreaseDecreaseTaxCutsAndJobsAct
|
3500000 | USD |
CY2021Q1 | prta |
Deferred Tax Asset Period Increase Decrease American Rescue Plan Act
DeferredTaxAssetPeriodIncreaseDecreaseAmericanRescuePlanAct
|
900000 | USD |